chr9-95482006-G-A
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2PM5PP2PP3PP5
The NM_000264.5(PTCH1):c.689C>T(p.Thr230Ile) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. T230P) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000264.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PTCH1 | NM_000264.5 | c.689C>T | p.Thr230Ile | missense_variant | 5/24 | ENST00000331920.11 | NP_000255.2 | |
PTCH1 | NM_001083603.3 | c.686C>T | p.Thr229Ile | missense_variant | 5/24 | ENST00000437951.6 | NP_001077072.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PTCH1 | ENST00000331920.11 | c.689C>T | p.Thr230Ile | missense_variant | 5/24 | 5 | NM_000264.5 | ENSP00000332353 | A2 | |
PTCH1 | ENST00000437951.6 | c.686C>T | p.Thr229Ile | missense_variant | 5/24 | 5 | NM_001083603.3 | ENSP00000389744 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Gorlin syndrome Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 09, 2017 | A different missense substitution at this codon (p.Thr230Pro) has been reported as de novo in an individual affected with Gorlin syndrome (PMID: 15459969) and is therefore considered to be pathogenic. This suggests that the threonine residue is critical for PTCH1 protein function and that other missense substitutions at this position may also be pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has been reported in an individual with suspected Gorlin syndrome in the Leiden Open-source Variation Database (PMID: 21520333). This variant is not present in population databases (ExAC no frequency). This sequence change replaces threonine with isoleucine at codon 230 of the PTCH1 protein (p.Thr230Ile). The threonine residue is highly conserved and there is a moderate physicochemical difference between threonine and isoleucine. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Sep 08, 2023 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 02, 2023 | The p.T230I variant (also known as c.689C>T), located in coding exon 5 of the PTCH1 gene, results from a C to T substitution at nucleotide position 689. The threonine at codon 230 is replaced by isoleucine, an amino acid with similar properties. This alteration has been observed in multiple individuals who have a personal or family history that is consistent with PTCH1-associated disease (Ambry internal data). Based on internal structural analysis, the threonine at codon 230 is an important phosphorylation site for protein-protein interactions (Ambry internal structural data; Foord R et al. Nat. Struct. Biol. 1999 Feb;6:157-65; Arnfors L et al. Acta Crystallogr. D Biol. Crystallogr. 2006 Sep;62:1085-97; Cuneo MJ et al. BMC Struct. Biol. 2008 Mar;8:20). In line with the importance of this amino acid residue, two other alterations at this position have been observed in Gorlin Syndrome patients, including in a de novo case: p.T230P and p.T230R (Savino M et al. Hum. Mutat., 2004 Nov;24:441; Reinders MG et al. Mol Genet Genomic Med, 2018 05;6:409-415). This amino acid position is highly conserved in available vertebrate species. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this alteration is interpreted as a disease-causing mutation. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 31, 2022 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at